Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly, Boehringer Ingelheim Partnership Bears Fruit

Thursday, December 17, 2015 07:10 AM EDT Updated: Thursday, December 17, 2015 08:25 AM EDT
Lilly, Boehringer Ingelheim Partnership Bears Fruit Lilly says the product received hit the market December 15.

An injectable insulin co-developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has received approval from the U.S. Food and Drug Administration. Basaglar, which is made in partnership with Boehringer Ingelheim Pharmaceuticals Inc., represents a significant boost for the Lilly Diabetes pipeline and is the first insulin therapy from the Lilly/BIPI collaboration to hit the market.

The partnership launched in 2011.

Basaglar is delivered using pre-filled "KwikPen" technology. It treats high blood sugar conditions in patients with Type 1 and Type 2 diabetes.

Lilly Diabetes Vice President of Global Medical Affairs David Kendall says "Lilly has a long history of developing and manufacturing insulin, having introduced the world’s first commercial insulin more than 90 years ago. BASAGLAR will be a welcome addition to our insulin and alliance portfolios, offering an option for people with diabetes who may need a long-acting insulin."

The treatment received preliminary approval late last year, but needed to clear patent litigation hurdles before securing the final go-ahead.

Basaglar has now received 11 global regulatory approvals.

Story Continues Below

Most Popular Stories

  • Commercial air service slated to return to Purdue Airport

  • Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

  • Why the NCAA president is proposing some schools should be permitted to pay athletes

  • Purdue board approves business school construction, tuition freeze

  • Choc-Ola maker looking to bring iconic drink back to stores

  • Palmer Trucks relocates, expands Fremont dealership

Perspectives

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

In the hustle and bustle of our professional lives, we often find ourselves engrossed in the intricacies of our trades. However, amidst our daily routines, there exists a unique opportunity to broaden our horizons and delve into the critical issues facing the state of Indiana. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service